Methane-forming microbes of the phylogenetic domain Archaea are part of the strictly anaerobic microflora of the human intestine. In bone marrow transplant (BMT) recipients, the regimen of intestinal decontamination with metronidazole is targeted to anaerobic bacteria. The effect on the anaerobic methanoarchaea, however, is unknown. Therefore, the faeces of patients undergoing BMT were investigated for methane production. The anoxic Hungate technique and an archaeal growth medium were used to culture faecal specimens. Methane production was measured in the head space of the culture bottles by gas chromatography using a thermal conductivity detector. In a testing serial specimen of 100 patients, 13 patients were found to bear methanogens, and 11 of these patients received metronidazole. The methaneproducing faecal specimens occurred before metronidazole use in three patients, during the first week in five patients, and after cessation in three patients. No specimen of the 11 patients that was obtained during the 2nd-5th week of gut decontamination showed methane production. It is concluded that use of metronidazole directed against faecal anaerobic bacteria also suppresses or eliminates faecal methanogenic Archaea.
methanogenic Archaea; metronidazole; intestinal decontamination; bone marrow transplantation The modern, phylogenetic taxonomy of organisms distinguishes three domains: Eukarya (formerly eukaryotes), Bacteria (formerly eubacteria) and Archaea (formerly archaebacteria). 1 The new entity Archaea includes microbes such as halophiles and thermophiles, living in extreme environmental conditions, and methanogens. These strictly anaerobic microbes are ubiquitous in diverse environments associated with decomposition of organic matter or geochemical activity, for example aquatic sediments, bogs and sewage digestors. In association with animals, methanogens occur in the rumen of herbivores, and the gut of various insects and vertebrates. 2 Methanogens also colonize the human intestinal tract, where Methanobrevibacter smithii is the most dominant species. 3 It was shown recently that isolates of M. smithii from human faeces are highly resistant against antibacterial antibiotics of the groups of blactames, aminoglycosides, glycopeptides, lincosamines, and fluorochinolones, but are sensitive to metronidazole. 4 In bone marrow transplant (BMT) recipients, prophylactic administration of metronidazole diminished the frequency of grades II-IV acute graft-versus-host disease (GVHD). 5, 6 This effect was attributed to the suppression of anaerobic bacteria, thus reducing the main bacterial load in the bowel and reducing immunostimulation by bacterial lipopolysaccharides and other bacterial components. Faecal methanogens were not in the scope of these investigations, as Archaea have been discovered quite recently and as they are widely ignored by clinical microbiologists in general.
In the present investigation, therefore, methane production, which is a specific sign of the presence of methanogens, 7 was examined in faecal specimens from BMT recipients and compared with the course of metronidazole administration.
Patients and methods

Sampling of specimens and conventional cultures
Faecal specimens of BMT patients were sent to the microbiological laboratory regularly twice weekly. They were quantitatively investigated for growth of aerobic and anaerobic bacteria as well as yeasts, using a plate count technique and selective growth media as described previously. 8 Specimens were additionally examined for methane production until 100 patients had been recorded, yielding approximately 600 specimens. At this stage of investigation, only the name of the patients and no clinical data were known to the laboratory, and only the conventional cultures and not the methane examinations were known to the clinicians.
Determination of methane production
The serum bottle modification of the Hungate technique was used. 9 Approximately 1 g of faecal material was inoculated into 100-ml serum bottles (Wheaton, Milleville, USA) containing 40 ml basal growth medium for methanogens, 4 which was supplemented with 6 mg/l vancomycin and 8 mg/l meropenem. The bottles were sealed, pressured to 200 kPa with 80% H 2 -20% CO 2 , and incubated at 371C for up to 3 weeks. At weekly intervals, the presence of methane was measured in the headspace of the bottles. A micro-gas chromatograph P 200 H (Hewlett-Packard, Wilmington, USA) with thermal conductivity detector, molecular sieve column MS5A, and helium as carrier gas was used.
The sample volume was 2 ml, the column temperature 801C, and the running time 100 s. Calibration was performed with standardized gases containing CH 4 (1.0%), CO 2 , CO, H 2 , O 2 , N 2 , and CH 4 (0.01%), N 2 , respectively (Supelco, Bellefonte, USA). M. smithii DSM 861 was used for growth control. Faecal samples producing more than 100 ppm (0.01%) methane were regarded as containing methanogenic Archaea.
Combining microbiological and clinical data
After completing the microbiological investigations, patients bearing methanogens were identified. The clinical records of these patients were reviewed with regard to the stage of BMT and duration of gut decontamination at the time of stool sampling. Patients undergoing allogeneic BMT received metronidazole 400 mg three times daily p.o., ciprofloxacin 750 mg twice daily p.o., and fluconazole 200 mg once daily p.o. Patients undergoing autologous transplantation received ciprofloxacin and fluconazole. Antibiotics were started 2 weeks before transplantation and continued up to 5 weeks after transplantation.
Results
Methane-producing faecal specimens were found in 13 of the 100 patients surveyed. Two of the methanogen-bearing patients had an autologous transplant and did not receive metronidazole. The other 11 patients were allogeneic BMT recipients receiving a gut decontamination regimen including metronidazole. The duration of metronidazole use ranged from 20 to 48 days, with a mean of 35 days. Methaneproducing specimens were obtained before metronidazole started in three patients, during the first week of metronidazole use in five patients, and after 4 and more weeks of metronidazole use in three patients (Table 1) . Specimens obtained during the 2nd to 5th week of metronidazole therapy and in the first month after metronidazole did not show methane production.
The methanogen-containing samples produced between 0.41 and 2.46% methane after 3 weeks of incubation (Table 1 ). However, given a limit value of 0.01% methane, all specimens were positive after 2 weeks of incubation, and six of the 11 specimens were positive after 1 week of incubation. An incubation period of 2 weeks, therefore, was sufficient to reveal specimens containing methanogens. The control strain M. smithii DSM 861 produced 1.0-1.2% methane after 3 weeks of incubation when the initial inoculum was 10 5 -10 6 cells/test bottle. Eight of the 11 specimens showed methane production in the same range or even higher (Table 1) . Thus, their initial contents of methanogens were at least 10 3 CFU/g in methane-producing and nonmethane-producing samples. Table 1 Occurrence of methanogenic Archaea in the faeces of allogeneic BMT recipients in relation to the application of metronidazole f=female; m=male; AML=acute myelogenous leukemia; CML=chronic myeloid leukemia; MM=multiple myeloma; nt=no specimen tested; 0=specimen with o100 ppm methane.
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None of the 11 allogeneic BMT recipients, with methanogens in the pretransplant period or after metronidazole but who were free of methanogens during the 2nd-5th week of metronidazole use, developed grades II-IV acute GVHD. Grade I acute GVHD was recorded in two patients.
Discussion
Intestinal colonization with methanogens is often acquired in the first weeks after birth, 10 and probably all human adults harbour methanogens in their large intestine. 3 The number of methanogens per gram of faeces may vary from only a few to about 10 10 cells. 3 In the present study population of 100 patients, 13% were identified with an estimated number of at least 10 5 -10 6 methanogens per gram of faeces. This figure corresponds to results obtained from healthy subjects using a similar method of faecal culture. Out of 49 subjects, 16% had faecal methanogens at X10 6 /g. 11 With the chosen threshold of X100 ppm headspace methane as positive for methanogens, heavily colonized patients were selected to evaluate the effect of metronidazole use. This selection must not be confounded with the prevalence of methanogens that may be much higher than 13% but needs quantifications by more selective isolation techniques.
11
The general features of archaeal microbes lacking structural and metabolic targets that are characteristics of bacteria as well as tests using a non-standardized qualitative paper-stripe agar diffusion technique suggested resistance of Archaea to most antibacterial antibiotics. 12 Recently, a standardized quantitative susceptibility test and therapeutic interpretation criteria were applied to investigate the effect of antibiotics on faecal isolates of M. smithii. 4 The minimum inhibition concentrations (MIC) of metronidazole ranged between 0.5 and 64 mg/l. As the faecal concentrations of metronidazole reached under therapeutic conditions exceed the highest MIC-values, the methanogenic isolates were regarded as susceptible to metronidazole. The present findings in patients corroborate the in vitro susceptibility data. Of the 13 methanogenbearing patients, two received no metronidazole. In the 11 patients receiving metronidazole, methanogenic cultures were obtained before or in the first week of metronidazole therapy and were followed by methane negative cultures (eight patients), or were obtained at least 4 weeks after the cessation of metronidazole (three patients). Gut decontamination with metronidazole obviously suppressed or eliminated the methanogens just as it did in the anaerobic bacteria. 6 Recolonization with methanogens may occur several weeks after metronidazole therapy.
Previous studies indicated that gut decontamination using metronidazole in BMT recipients significantly reduces the development of acute GVHD. 5, 6 The effect was attributed to the reduction of the dominant resident anaerobic bacterial flora resulting in a decreased translocation of bacterial products into the portal and systemic circulation, which are able to induce an alloantigenindependent inflammatory process. 6 An alternative or additional and more specific mechanism of modulating acute GVHD by intestinal decontamination may be the elimination of microbes sharing antigens with the host tissue, thus diminishing the activation of alloreactive donor T-cell clones. 13 However, the microbes that may play a significant role in this context have not yet been identified.
Intestinal Archaea that have not been noted in earlier studies are candidates for such a crossreaction, particularly since they share more characteristics with eukaryotic cells than bacteria.
14 The acute GVHD-diminishing effect of gut decontamination by metronidazole may be attributed, therefore, to the elimination of methanogenic Archaea rather than to the suppression of anaerobic bacteria. However, extended experimental and clinical studies are needed to clarify whether or not intestinal Archaea contribute to the development of acute GVHD after human bone marrow transplantation.
